Gustav Christensen

Gustav A. Christensen currently works at Morphic Therapeutic, Inc., as Chairman and Phytera, Inc., as President, Treasurer & Director.
Mr. Christensen also formerly worked at Dyax Corp., as President, Chief Executive Officer & Director from 2011 to 2016, Alpha-Beta Technology, Inc., as Chairman, Morphic Holding, Inc., as Chairman from 2016 to 2024, Apeiron Partners LLC, as Managing Director from 2005 to 2007, Generation Bio Co., as Independent Director from 2017 to 2026, Genetics Institute LLC, as Vice President-Business Development from 1983 to 1988, ImmuLogic Pharmaceutical Corp., as President, BioVentures Investors, as Advisor, Alantos Pharmaceuticals AG, as Member-Management Board, and Baxter International, Inc., as Vice President-Operations Fenwal Laboratories from 1976 to 1983.
Mr. Christensen received his graduate degree from the University of Aarhus and Masters Business Admin degree from Harvard Business School.